Pancreatic Cancer Treatment Patents Applied For - 2 February 2012

Astrimmune is poised to announce new patent applications for the treatment of pancreatic cancer. Paul Broome, the primary inventor and Astrimmune's medical director commented that this was just the beginning of what was hoped to be a series of patent applications.

Fred Jacobs, Astrimmune's CEO, stated that this was a necessary step to prepare for collaborations to develop biomarkers and for a pivotal trial for pancreatic cancer.

Astrimmune is developing treatments for gastrointestinal cancers with its first product aimed at pancreatic cancer. Astrimmune has secured US Orphan Drug Status for pancreatic cancer.